First half 2018 | Novartis

First half 2018 | Novartis


In January I laid out a
strategy where I wanted our company to become a leading medicines
company powered by data and digital. And we’ve taken action throughout the first half
of the year to make that vision a reality. First we announced the sale of our
GSK OTC joint venture stake for 13 billion dollars. We also announced that we’ll be
creating the leading medical device ophthalmology company in the world with the
spin of Alcon to our shareholders. Alongside the moves to exit those areas and focus
as a medicines company, we’ve also made important investments. We’ve completed the acquisition of
Advanced Accelerator Applications, a leading oncology company as well as the
acquisition of AveXis to put us in a position to lead
in gene therapies into the future. I believe the future of
Novartis is going to be critically driven by our culture, to
create an inspired, curious unbossed culture. We’ve done a number of things to progress
that already in the first half of this year. We’ve built a new executive leadership team that
I believe is one of the best in the industry and I’m very proud to
build this team and have it come together. I believe the future of our
industry is dependent on truly breakthrough innovation; breakthrough efficacy that can truly deliver
value for patients, payers and society. I believe we made great
progress on that in the quarter. We launched Aimovig,
our breakthrough in migraine. We received approval for our Kymriah medicine for
patients with cancer in Europe and importantly we also acquired AveXis, a leading gene therapy company
which I believe will put us in a position to hopefully become one of the leaders
in gene therapy well into the future. I believe operational excellence everyday is going to
be critical to our future so we can become more productive, improve our
margins and be able to invest in R and D as well as
our medical and marketing and sales efforts. In the first half, we started
major initiatives in our business service area as well as in our
technical operations to drive really renewed efficiency. I want Novartis to go big on data
and digital because I believe our future is going to be driven by our ability to drive
data science and digital technologies across the company. We’ve launched 12 digital lighthouse
initiatives that are transforming how we operate, how we innovate and
how we sell our medicines. We’ve also made very concrete investments
like our collaboration with Pear Therapeutics to bring truly digital therapeutics
to patients in the United States. I believe as a leading healthcare company
we need to return more to society. But first that starts with living
our values, our ethics every single day. We can’t compromise on our
values and integrity in our daily work and we’re making that
clear at every level at Novartis. We’re also making important
commitments to improving global health. This includes our hundred million dollar
commitment to malaria and malaria research. Our commitment to global leprosy
elimination, as well as a range of other commitments including advancing
our work with Novartis Access to bring medicines for non-communicable diseases
to patients across poorer countries. I’m proud of what we do every single day
to deliver medicines to patients all around the world. We have more work to do
but I believe we’ve started off on a strong footing to become the
leading medicines company we aspire to be.

Leave a Reply

Your email address will not be published. Required fields are marked *